Additionally, the pre-treatment with ANA12, a TrkB antagonist, has been reported to block BDNF signaling and exacerbate cognitive impairments [27], further suggesting the BDNF signaling through TrkB is closely linked to cognitive dysfunction. The gene discussed is NTRK2; the disease is Cognitive impairment.